Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 2Urothelial Cancer 1Ureteral Neoplasms 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × vinflunine × 1 year × Clear all
NCT04527991 2026-06-02

TROPiCS-04

Gilead Sciences

Phase 3 Completed
711 enrolled 25 charts
Genitourinary

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT07419295 2026-05-29

TroFuse-031

Merck Sharp & Dohme LLC

Phase 3 Recruiting
590 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting
629 enrolled 32 charts
Genitourinary

Urothelial Cancer

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡